1004 related articles for article (PubMed ID: 15066127)
41. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
42. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
43. A comparison of the effect on dispersion of repolarization of age-adjusted MAC values of sevoflurane in children.
Whyte SD; Sanatani S; Lim J; Booker PD
Anesth Analg; 2007 Feb; 104(2):277-82. PubMed ID: 17242080
[TBL] [Abstract][Full Text] [Related]
44. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins.
Dumotier BM; Georgieva AV
Cell Biol Toxicol; 2007 Jul; 23(4):293-302. PubMed ID: 17216548
[TBL] [Abstract][Full Text] [Related]
45. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
46. Fast and slow torsade de pointes--electrocardiographic characteristics.
Kukla P; Słowiak-Lewińska T; Szczuka K; Plato A; Bromblik A; Hajduk B; Kluczewski M; Przewor M
Kardiol Pol; 2004 Apr; 60(4):342-7. PubMed ID: 15226783
[TBL] [Abstract][Full Text] [Related]
47. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
Fazekas T; Liszkai G
Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
[TBL] [Abstract][Full Text] [Related]
48. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3.
Milberg P; Reinsch N; Osada N; Wasmer K; Mönnig G; Stypmann J; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Jul; 100(4):365-71. PubMed ID: 15944809
[TBL] [Abstract][Full Text] [Related]
49. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias.
Furukawa T; Kurokawa J
Pharmacol Ther; 2007 Jul; 115(1):106-15. PubMed ID: 17583354
[TBL] [Abstract][Full Text] [Related]
50. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
51. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
52. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
Antzelevitch C
Heart Rhythm; 2005 Nov; 2(2 Suppl):S9-15. PubMed ID: 16253930
[TBL] [Abstract][Full Text] [Related]
53. Proarrhythmic potential of antimicrobial agents.
Simkó J; Csilek A; Karászi J; Lorincz I
Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
[TBL] [Abstract][Full Text] [Related]
54. Sex hormonal regulation of cardiac ion channels in drug-induced QT syndromes.
Kurokawa J; Kodama M; Clancy CE; Furukawa T
Pharmacol Ther; 2016 Dec; 168():23-28. PubMed ID: 27595633
[TBL] [Abstract][Full Text] [Related]
55. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
56. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
57. [Sotalol and torsades de pointes ventricular tachycardia].
Petersen HH; Sandøe E
Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
[TBL] [Abstract][Full Text] [Related]
58. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes.
Thomsen MB; Volders PG; Beekman JD; Matz J; Vos MA
J Am Coll Cardiol; 2006 Sep; 48(6):1268-76. PubMed ID: 16979017
[TBL] [Abstract][Full Text] [Related]
59. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
60. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
Lawrence KR; Nasraway SA
Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
